At a glance
An albumin-binding GHRH analogue studied for prolonged endocrine activity.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited research examines GH and IGF-1 responses. Changes in hormone measurements do not independently establish improvements in strength, recovery or longevity.[3][4][10]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 DAC.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 2 mg · 1 source tables
Standard Weekly Approach (1 mL = 2.0 mg/mL)
| Week | Weekly Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Frequency: Inject once weekly subcutaneously, preferably in the evening before bed to align with natural nocturnal GH surges[5]. The peptide’s extended half-life (~6–8 days) supports weekly administration without significant loss of activity between doses[1].
Additional schedule context & duration
Concise summary of the once-weekly regimen.
- Goal: Elevate endogenous GH and IGF-1 levels to support muscle growth, fat metabolism, recovery, and anti-aging research[3][4].
- Schedule: Weekly subcutaneous injections for 8–12 weeks.
- Dose: 2,000 mcg (2 mg) once weekly — one full vial per injection.
- Reconstitution: 1.0 mL per 2 mg vial (2.0 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested weekly administration approach.
- Standard Dose: 2,000 mcg (2 mg) once weekly[1].
- Conservative Option: 1,000 mcg (1 mg) weekly if exploring lower doses.
- Frequency: Once per week (subcutaneous).
- Cycle Length: 8–12 weeks; optional 4-week break between cycles.
- Timing: Evening administration (pre-bed) may synergize with natural nocturnal GH release; rotate injection sites weekly[5].
Preparation
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and efficacy.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw[6].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][8].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch about an inch of skin at the injection site (lower abdomen, outer thigh, or upper arm)[8].
- Insert the needle at a 90° angle into the pinched fold (use 45° if minimal subcutaneous fat)[8].
- Depress the plunger fully, then withdraw the needle and dispose in a sharps container.
- Rotate sites weekly to prevent lipohypertrophy — for example, alternate between left and right abdomen[8].
Materials & quantity planning
Source materials checklist · 2 mg
Plan based on an 8–12 week weekly protocol.
-
Peptide Vials (CJC-1295 DAC, 2 mg each):
- 8 weeks: 8 vials (1 vial/week)
- 12 weeks: 12 vials (1 vial/week)
-
Insulin Syringes (U-100, 1 mL capacity):
- Per week: 1 syringe
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
-
Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution.
- 8 weeks (8 vials): 8 mL → 1 × 10 mL bottle
- 12 weeks (12 vials): 12 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs → recommend 1 × 100-count box
- 12 weeks: 24 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 2 mg per vial and 1 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Clinical Pharmacology & Therapeutics — DAC technology: albumin-binding for extended peptide half-life (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Body composition and quality of life in adults with GH deficiency; effects of GH replacement (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PubMed — Physiology of growth hormone secretion during sleep (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Bachem — Handling and storage guidelines for peptides (opens in a new tab)www.bachem.com
Back to overview ↑ - 07
Public health resource
CDC — Preventing unsafe injection practices and clinical safety guidelines (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
MedlinePlus — Subcutaneous (SQ) injections: technique, site selection, and rotation (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Source document
Endocrine Reviews — GHRH analogs and preservation of pulsatile GH secretion patterns (opens in a new tab)academic.oup.com
Back to overview ↑ - 10
Research publication
PubMed — Effect of tesamorelin on visceral fat in HIV-infected patients: randomized clinical trial (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 11
- 12
Research publication
J Clin Endocrinol Metab (2006) — Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
J Clin Endocrinol Metab (2006) — Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 14
Public health resource
StatPearls (NCBI Bookshelf) — Brinkman JE et al. Physiology, Growth Hormone (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
- 16
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (patient guidance) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 17
Public health resource
StatPearls (NCBI Bookshelf) — Regular Insulin: subcutaneous administration and site rotation (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 18
- 19
Research publication
Postgrad Med J (2006) — Ayuk J, Sheppard MC. Growth hormone and its disorders (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 20
Research publication
Am J Physiol Endocrinol Metab (2006) — Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.